VKTX earnings call for the period ending December 31, 2019.
News & Analysis: Viking Therapeutics
Targeting a large and growing disease state, this drug developer's stock requires patience to reap future rewards.
Can the stock march even higher after its recent rally?
The biotech's Q3 update fired up investors.
The biotech rivals each aim to dominate the treatment market for non-alcoholic steatohepatitis (NASH).
These small-cap stocks hold the potential to deliver big-time returns.
What you need to know about this high-risk, high-reward biotech stock.
VKTX earnings call for the period ending June 30, 2019.
It's one of the more promising companies in the race to develop a successful NASH treatment. Will patient investors be rewarded?
The catalysts these companies enjoy could translate into big returns for shareholders in the coming decades.